Suppr超能文献

潜伏性结核(LTBI)治疗:印度面临的挑战及对 2025 年的展望:“治疗 LTBI 还是不治疗,这是个问题”。

Latent TB (LTBI) treatment: Challenges in India with an eye on 2025: "To Treat LTBI or not to treat, that is the question".

机构信息

Chest Specialist, New Delhi TB Centre, India.

Vice Chairman Publication & Research, Honorary Treasurer, Honorary Technical Advisor, TB Association of India, India.

出版信息

Indian J Tuberc. 2020 Dec;67(4S):S43-S47. doi: 10.1016/j.ijtb.2020.09.028. Epub 2020 Oct 1.

Abstract

Latent tuberculosis infection (LTBI) is defined as a consistent immune response to Mycobacterium tuberculosis antigens without evidence of clinically evident active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations especially in high prevalent country like India. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI. Therefore an unequivocal policy /of diagnosis and treatment of LTBI will serve to ameliorate the standards of the Indian health scenario and bring the TB infection to the propinquity of its ultimate elimination.

摘要

潜伏性结核感染(LTBI)定义为对结核分枝杆菌抗原的持续免疫反应,而无临床明显活动性结核病(TB)的证据。LTBI 的诊断和治疗对于结核病很重要,特别是在高危人群中,尤其是在印度等结核病高发国家。结核菌素皮肤试验(TST)和干扰素-γ释放试验(IGRAs)用于诊断 LTBI。因此,明确的 LTBI 诊断和治疗政策将有助于改善印度卫生状况的标准,并使结核病感染接近最终消除的目标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验